Latest Biotechnology, Pharmaceutical and Healthcare News from Thomson Reuters

For Bifurcation Lesions in Coronary Arteries, Medtronic's Resolute Stent Delivers Strong Long-Term Results

Three Analyses Presented at EuroPCR Demonstrate Device's Durability in Addressing Common Clinical Challenge PARIS -- May 22, 2013 -- Addressing one of the most common clinical challenges in the treatment of complex coronary artery disease, three separate analyses on the program for EuroPCR this week show how strongly the Resolute drug-eluting stent from Medtronic, Inc. (NYSE: MDT) performs...

Medtronic Announces CE Mark and Launch for CapSureFix Novus(TM) 5076 MRI Lead

Proven Lead Expands Access to MRI for Patients with Slow Heartbeat TOLOCHENAZ - May 21, 2013 -- Medtronic today announced CE Mark (Conformité Européenne) and launch of its CapSureFix Novus(TM)5076 Lead, which is now approved in the EU  for use in an MRI environment when paired with a Medtronic MR-Conditional pacemaker. The lead has not been approved for that use in the U.S. The CapSureFix No...

New data reinforces strength of Novartis once-daily COPD portfolio in improving lung function, shortness of breath and reducing rate of exacerbations

Novartis International AG / New data reinforces strength of Novartis once-daily COPD portfolio in improving lung function, shortness of breath and reducing rate of exacerbations . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. BLAZE study showed once-daily QVA149 significantly improved patient self-reported shortness of b...

Fourth Quarter Caps Solid Year for Medtronic

Q4 Revenue of $4.5 Billion Grew 5% at Constant Currency; 4% as Reported Q4 Non-GAAP Diluted EPS Growth of 11%; GAAP Diluted EPS Growth of 1% Q4 International Revenue Grew 7% at Constant Currency; 4% as Reported FY13 Revenue of $16.6 Billion Grew 5% at Constant Currency; 3% as Reported FY13 Free Cash Flow of $4.4 Billion; GAAP Cash Flow from Operations of $4.9 Billion

SuppreMol Raises € 9.5 million in Extended Series D Financing Round

SuppreMol GmbH / SuppreMol Raises € 9.5 million in Extended Series D Financing Round . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. Munich, Germany, May 21st, 2013: SuppreMol GmbH, a privately held biopharmaceutical company developing novel therapies for the treatment of autoimmune diseases, today announced the second cl...

Medtronic's Multi-Electrode, Simultaneously Firing Renal Denervation Catheter Shows Reduced Procedure Times While Demonstrating Significant Blood Pressure Reduction

Initial Results from Feasibility Study of the Symplicity Spyral(TM) Catheter Show Safety and Efficacy While More than Halving Mean Procedure Time MINNEAPOLIS and PARIS - MAY 21, 2013 - Medtronic, Inc. (NYSE: MDT) announced today preliminary results from the feasibility study of its Symplicity SpyralTM multi-electrode, 6 Fr renal denervation catheter, which showed safe, significant blood pressur...

Medtronic Finds TAVI with CoreValve® System Cost Effective for Treating Patients with Severe Aortic Stenosis

EuroPCR Presentation of "Real World" ADVANCE Study Confirms Economic Value of Novel Self-Expanding Valve in Patients Unable to Undergo Surgery PARIS -- May 21, 2013 -- Focused on offering devices that provide both clinical and economic value, Medtronic, Inc. (NYSE: MDT) today unveiled the results of a cost-effectiveness model comparing transcatheter aortic valve implantation (TAVI) wi...

Medtronic Announces Data From Largest Real-World Patient Population Confirm Strong Safety Profile and Clinical Efficacy of Renal Denervation with the Symplicity(TM) System

First Look at Data from Global SYMPLICITY Registry Shows Renal Denervation with the Symplicity(TM) System Meets Performance Expectations in Real-World Setting MINNEAPOLIS and PARIS - MAY 21, 2013 - Medtronic, Inc. (NYSE: MDT), announced today the first results from the Global SYMPLICITY Registry, which reaffirmed the safety of the renal denervation procedure with the Symplicity(TM) renal dener...

Medtronic CoreValve ADVANCE Study Demonstrates Low Rates of Mortality and Stroke and Sustained Valve Performance

EuroPCR Presentation of One-Year Data from Robust "Real World" Global Study Demonstrates One of the Lowest Mortality Rates among Similar TAVI Studies PARIS -- May 21, 2013 -- Committed to generating robust clinical data on its CoreValve System for transcatheter aortic valve implantation (TAVI), Medtronic, Inc. (NYSE: MDT) today unveiled for the first time the complete one-year data fr...

Ossur Hf : Össur acquires TeamOlmed in Sweden

Announcement from Össur hf. No:15/2013Reykjavik, 21 May 2013      Össur acquires TeamOlmed in Sweden Össur has today signed an agreement to acquire 100% of the shares of TeamOlmed, a leading Swedish orthotic and prosthetic (O&P) provider, for SEK 310 million (USD 47 million).  Additional payments of up to SEK 50 million (USD 7 million) depend on TeamOlmed meeting certain revenue a...

Addex Validates Potential Efficacy Biomarker for Phase 1 Trial of its GABA-B Positive Allosteric modulator, ADX71441

Addex Therapeutics / Addex Validates Potential Efficacy Biomarker for Phase 1 Trial of its GABA-B Positive Allosteric modulator, ADX71441 . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.   ·         ADX71441 produced dose-dependent changes on growth hormone (GH) plasma concentrations in a preclinical model·  ...

Largest-ever global survey of 1,273 women in 12 countries reveals women with advanced breast cancer feel left out of the breast cancer movement

Novartis International AG / Largest-ever global survey of 1,273 women in 12 countries reveals women with advanced breast cancer feel left out of the breast cancer movement . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. Breast cancer is the most common cancer in women worldwide, yet survey confirms many women living with...

Medtronic to Honor Those Who Give Back After Receiving Life-Enhancing Medical Technology

(View the Bakken Invitation video here) Live On. Give On:  Ten inspirational people will be awarded a $20,000 charitable donation and be honored at an awards celebration in Hawaii as part of the first annual Bakken Invitation MINNEAPOLIS - May 20, 2013- Medtronic, Inc. (NYSE: MDT) announced today that applications are being accepted for the inaugural Bakken Invitation, a global program desig...

WellCare Medicare Advantage Members Now Covered At Walgreens Take Care Clinics

TAMPA, Fla. (May 20, 2013) - WellCare Health Plans, Inc. (NYSE: WCG) recently entered into an agreement with Take Care Health Systems, a subsidiary of Walgreens (NYSE, Nasdaq: WAG), to offer its Medicare Advantage members access to the more than 370 Take Care Clinics located at select Walgreens stores in 19 states and Washington, D.C.  As of March 2013, WellCare serves more than 256,000 Medic...

Medtronic Receives 'CE' Mark for 'Export Advance' Aspiration Catheter

Backed by Robust Clinical Data on Broad Product Family, New Thrombus Removal System Offers Superior Deliverability MINNEAPOLIS -- May 20, 2013 -- Expanding its portfolio of medical technology for the interventional treatment of cardiovascular disease, Medtronic, Inc. (NYSE: MDT) announced today that the Export Advance aspiration catheter recently received the CE (Conformité Européenne) mark...

Orion Corporation is preparing to issue a bond

    ORION CORPORATION        STOCK EXCHANGE RELEASE 20 MAY 2013 at 09.50 EEST               Orion Corporation is preparing to issue a EUR 100-150 million senior, unsecured bond that would mature in 5-7 years. Also, an application would be made to have the bond listed on NASDAQ OMX Helsinki. The proceeds from the bond offering would be used for general corporate purposes. Orion Co...

225,000 Orion A-shares converted into B-shares

    ORION CORPORATION        STOCK EXCHANGE RELEASE 20 MAY 2013 at 09.15 a.m. EEST               In accordance with Section 3 of the Articles of Association of Orion Corporation, 225,000 A-shares have been converted into 225,000  B-shares. The conversion has been entered into the Trade Register on 20 May 2013. The total number of shares in Orion Corporation is 141,257,828  wh...

DENTSPLY International Inc. to Present at the UBS Global Healthcare Conference

York, PA - May 17, 2013 - DENTSPLY International Inc. (NASDAQ-XRAY) today announced that Chris Clark, President and Chief Financial Officer, will be presenting at the UBS Global Healthcare Conference at The Sheraton New York Hotel in New York City on Monday, May 20, 2013.    DENTSPLY International Inc. is a leading manufacturer and distributor of dental and other consumable medical device p...

Novartis drug Afinitor® significantly extended time without disease progression in women with HER2 positive advanced breast cancer

Novartis International AG / Novartis drug Afinitor® significantly extended time without disease progression in women with HER2 positive advanced breast cancer . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. Everolimus plus trastuzumab and vinorelbine met primary endpoint of extending PFS compared to placebo plus trastu...

Galapagos creates new warrant plan

Mechelen, Belgium; 17 May 2013 - Galapagos NV (Euronext: GLPG) announced today that its Board of Directors created 648,490 warrants under a new warrant plan for the benefit of employees, directors and independent consultants of the Company and its subsidiaries. On 16 May 2013, the Board of Directors of Galapagos approved the "Warrant Plan 2013" within the framework of the author...

Additional macitentan (Opsumit) data in pulmonary arterial hypertension presented at ATS

Actelion Pharmaceuticals Ltd / Additional macitentan (Opsumit) data in pulmonary arterial hypertension presented at ATS . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. ALLSCHWIL/BASEL, SWITZERLAND - 17 May 2013 - Actelion (SIX: ATLN) today announced that further data for its investigational drug macitentan (Opsumit®) wil...

Biofrontera publishes 1st quarter 2013 interim report

Biofrontera AG / Biofrontera publishes 1st quarter 2013 interim report . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. Leverkusen, Germany, 17 May 2013 - Biofrontera AG (DSE: B8F) has today published its interim report for the 1st quarter 2013 on its corporate webpage. Since Biofrontera is only obliged to report detailed fi...

Sobi appoints Mats-Olof Wallin as permanent Chief Financial Officer

Mats-Olof Wallin, who recently took on the role as interim Chief Financial Officer (CFO), has been appointed Senior Vice President and CFO at Swedish Orphan Biovitrum AB (publ.) (Sobi). After a thorough search process supported by a senior Executive Search firm, Mats-Olof Wallin was selected as the preferred candidate. Wallin brings more than 30 years of experience in the pharmaceutical industry...

Galapagos business update

Mechelen, Belgium; 17 May 2013 - Galapagos NV (Euronext: GLPG) announced today that the operational and financial results achieved thus far in 2013 encourage the Company to retain full year 2013 Group revenues guidance of €160 million. "Galapagos has a maturing and broad pipeline of novel mode of action programs.  Our flagship program, GLPG0634, will start a large Phase 2b study next mon...

Novartis wins GBCHealth Business Action on Health Award for social ventures initiative

Novartis International AG / Novartis wins GBCHealth Business Action on Health Award for social ventures initiative . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. GBCHealth recognizes Novartis Arogya Parivar ("Healthy Family") initiative as one of the best corporate programs to address global health needs Ar...